
My original account @imacuriosguy has been impersonated by an idiot who has nothing to gain since I don't earn any revenue and the followers and mutuals are intelligent enough not to fall for the scams perpetrated by him.
Rajesh Parikh
120 posts

@ancvisit
Ob/Gyn for three decades plus. Vadodara. I deliver babies and inconvenient truths. Curious, eclectic, wabi-sabi. Found my Ikigai. Respectful but not agreeable.

My original account @imacuriosguy has been impersonated by an idiot who has nothing to gain since I don't earn any revenue and the followers and mutuals are intelligent enough not to fall for the scams perpetrated by him.


CBSE school principals safeguarding their careers by sacrificing the future of students.

CBSE rejects the allegations regarding the award of contract to Coempt Edutech. It is erroneous, misleading and not based on facts. CBSE has followed the General Financial Rules protocols scrupulously in the awarding of the contract to the agency. CBSE floated the RFP for Digital Evaluation of Answer books for Board Exams 2026 on Central Public Procurement portal on 28.08.2025 and awarded the contract to the qualified bidder. @dpradhanbjp @EduMinOfIndia @sanjayjavin @PIB_India @PIB_Edu @AkashvaniAIR @airnewsalerts @DDNewslive @PTI_News







Reading glasses might be done. The FDA just approved a once-daily eye drop called VIZZ that sharpens near vision in about 30 minutes and keeps it sharp for up to 10 hours. One drop. Each eye. Per day. That's it. The active ingredient is aceclidine, a compound first used back in 1975 to treat glaucoma. Scientists figured out it could be repurposed to gently shrink the pupil, creating a "pinhole effect" that pulls close-up text back into focus, the same trick your eye does when you squint. Unlike Vuity, the 2021 drop that came before it, VIZZ doesn't mess with your focusing muscles. So no blurry distance vision. No brow ache. No weird zoom effect. It was tested across more than 30,000 treatment days with no major complications. Cost is roughly $2 a day. This matters because presbyopia, the age-related slide that hits most people between 40 and 45, already affects more than 120 million Americans. By 2030, the World Health Organization expects around 2 billion people worldwide to have it. LENZ Therapeutics, the maker, started rolling out samples in October. The squint era is ending. Source: Ynetnews, FOX 26 Houston, Yahoo News

સંસ્કારોનો ઝંડો લઈને ફરતી ABVP પોતાના જ કાર્યક્રમમાં મર્યાદા ચૂકી, વિદ્યાર્થીનીના ડાન્સથી યુનિવર્સિટીની પ્રતિષ્ઠાને નુકસાન! #Vadodara #MSU


